Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

IOmx Therapeutics AG

Explore full profile

Developing next-generation targeted cancer immunotherapy treatments

Planegg, GermanyFounded 2016Biotech & Life Sciences
Valuation $100–500M Latest valuation · 2021
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for IOmx Therapeutics AG and the history behind them.

About IOmx Therapeutics AG

iOmx is a clinical-stage biotechnology company focused on developing next-generation targeted cancer immunotherapy treatments. The company leverages deep insights into tumor and myeloid biology, along with its proprietary iOTargTM target screening platform, to create novel treatments for prevalent solid tumor indications. iOmx translates unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs, aiming to develop drugs with single-agent activity that could serve as new backbone therapies across various modalities.

Read full description

The company primarily serves cancer patients, targeting the oncology market with its innovative treatments. iOmx operates on a business model centered around drug discovery and development, making money through venture capital investments and potential future revenues from drug sales and partnerships.

Backed by international venture capital investors such as ATHOS, Sofinnova Partners, Wellington Partners, MIG Capital, and M Ventures, iOmx is committed to shaping the future of cancer therapy through its comprehensive drug discovery and development expertise.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2016
Headquarters
Planegg, Germany
Employees
53
Open positions
None listed
Dealroom signal
69.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Oncology, Patient Care, Immune System, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b
Links
WebsiteLinkedIn

Latest news

Press, funding announcements and product moves mentioning IOmx Therapeutics AG.

See all news

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Jun 2025 $0 — Wellington Partners —
LATE VCOther financing Mar 2025 $0 — M Ventures · MIG Capital · Arvantis Group · ATHOS Biopharma —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

IOmx Therapeutics AG website traffic

Latest recorded traffic for IOmx Therapeutics AG is 970 monthly website visits, up 438.9% over the last three months. IOmx Therapeutics AG's team grew 0% over the past year.

Latest monthly visits970 3-month web change+438.9% 1-year team growth0%
Monthly website visitsNov 2017–Jul 2026
Explore monthly traffic historyTrack growth over time and compare with peersBook a demo
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
Spezialist Labororganisation –& betrieb / Lab Operations Specialist (m/w/d)Munich, Germany, Western Europe, Europe · Other · Sep 4, 2026 (Senior) Research Associate – Protein Science (gn)Munich, Germany, Western Europe, Europe · Other · Aug 28, 2026
2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
eTheRNA immunotherapiesMessenger RNA immunotherapies for cancer and infectious diseases Antwerp, Belgium Acquired 96 $115M $172M
Light Chain BioscienceFormerly Novimmune. Develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders Geneva, Switzerland Operational
EfranatAnticancer immunotherapy activating the body's immune system Rehovot, Israel Closed
Bright Peak TherapeuticsDeveloping next-generation immunotherapies, focusing on the treatment of cancer and autoimmune diseases Basel, Switzerland Operational
TollysDevelopment of innovative immunotherapies targeting cancer through the modulation of the TLR3 receptor Lyon, France Closed
Elicio TherapeuticsTransforming the lives of patients and their families by re-engineering the body’s immune response to cancer Cambridge, United States Operational
HiFiBiO TherapeuticsAn emerging clinical stage multinational company mobilizing the human immune system to treat cancer and autoimmune diseases Cambridge, United States Operational
BioNTechDevelops personalized immunotherapies with a focus on cancer medicine Mainz, Germany Operational
Showing 8 of the closest matchesCompare every metric →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • MPM BioImpact
  • Sofinnova Partners
  • Wellington Partners
  • M Ventures
  • MIG Capital
  • ATHOS Venture

Series B and later2 investors entered at this stage

  • Arvantis Group
  • ATHOS Biopharma

Other known investors2 additional known investors

  • DKFZ German Cancer Research Center
  • Helmholtz Association - Helmholtz Gemeinschaft

Talent

Book a demo to see the people
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇩🇪 Germany97.6%
🇬🇧 United Kingdom2.4%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about IOmx Therapeutics AG on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See IOmx Therapeutics AG’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.